Regeneron Pharmaceuticals Inc (REGN)
957.00
+19.39
(+2.07%)
USD |
NASDAQ |
May 03, 16:00
956.28
-0.72
(-0.08%)
After-Hours: 20:00
Regeneron Pharmaceuticals Research and Development Expense (TTM): 4.586B for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.586B |
| December 31, 2023 | 4.439B |
| September 30, 2023 | 4.305B |
| June 30, 2023 | 4.141B |
| March 31, 2023 | 3.850B |
| December 31, 2022 | 3.592B |
| September 30, 2022 | 3.287B |
| June 30, 2022 | 3.041B |
| March 31, 2022 | 2.961B |
| December 31, 2021 | 2.860B |
| September 30, 2021 | 2.867B |
| June 30, 2021 | 2.886B |
| March 31, 2021 | 2.894B |
| December 31, 2020 | 2.735B |
| September 30, 2020 | 2.543B |
| June 30, 2020 | 2.384B |
| March 31, 2020 | 2.548B |
| December 31, 2019 | 2.45B |
| September 30, 2019 | 1.782B |
| June 30, 2019 | 1.813B |
| March 31, 2019 | 1.456B |
| December 31, 2018 | 1.469B |
| September 30, 2018 | 2.113B |
| June 30, 2018 | 2.086B |
| March 31, 2018 | 2.066B |
| Date | Value |
|---|---|
| December 31, 2017 | 2.075B |
| September 30, 2017 | 2.026B |
| June 30, 2017 | 2.040B |
| March 31, 2017 | 2.090B |
| December 31, 2016 | 2.052B |
| September 30, 2016 | 2.034B |
| June 30, 2016 | 1.917B |
| March 31, 2016 | 1.748B |
| December 31, 2015 | 1.621B |
| September 30, 2015 | 1.511B |
| June 30, 2015 | 1.423B |
| March 31, 2015 | 1.327B |
| December 31, 2014 | 1.271B |
| September 30, 2014 | 1.188B |
| June 30, 2014 | 1.074B |
| March 31, 2014 | 967.03M |
| December 31, 2013 | 859.95M |
| September 30, 2013 | 772.83M |
| June 30, 2013 | 707.08M |
| March 31, 2013 | 666.99M |
| December 31, 2012 | 625.55M |
| September 30, 2012 | 573.57M |
| June 30, 2012 | 543.20M |
| March 31, 2012 | 538.98M |
| December 31, 2011 | 529.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.782B
Minimum
Sep 2019
4.586B
Maximum
Mar 2024
3.098B
Average
2.890B
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.163B |
| Amgen Inc | 5.069B |
| Eli Lilly and Co | 9.851B |
| Moderna Inc | 4.777B |
| Gilead Sciences Inc | 8.222B |